Atlas Trials

Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer

Clinical trial NCT07552181 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07552181
Sponsor
Yuan Yuan
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
TNBC - Triple-Negative Breast CancerTNBCEarly Stage Triple-Negative Breast Carcinoma
Start date
2026-09-01
Primary completion
2035-09-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.